CG
AXSM icon

Cynosure Group’s Axsome Therapeutics AXSM Stock Holding History

Cynosure Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$835K Buy
3,413
+796
+30% +$173K 0.13% 51
2026
Q1 		$442K Sell
2,617
-858
-25% -$148K 0.06% 108
2025
Q4 		$635K Sell
3,475
-4,369
-56% -$610K 0.06% 103
2025
Q3 		$953K Hold
7,844
– – 0.1% 80
2025
Q2 		$819K Buy
7,844
+2,439
+45% +$258K 0.09% 113
2025
Q1 		$630K Sell
5,405
-1,142
-17% -$130K 0.09% 134
2024
Q4 		$554K Sell
6,547
-1,383
-17% -$127K 0.08% 131
2024
Q3 		$713K Buy
+7,930
New +$692K 0.1% 123

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cynosure Group's AXSM Position: Q2 2026 in Review

Cynosure Group increased its Axsome Therapeutics (AXSM) stake by 30% in Q2 2026, buying an estimated $173K and bringing the position to 3,413 shares worth $835K. The position accounts for 0.13% of the portfolio, ranked #51.

Cynosure Group first reported a position in AXSM in Q3 2024 and has held it in 8 quarters since. The position peaked at $953K in Q3 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Cynosure Group held 3,413 shares of Axsome Therapeutics worth $835K as of Q2 2026.
  • Cynosure Group bought 796 Axsome Therapeutics shares in Q2 2026, an estimated $173K.
  • Axsome Therapeutics made up 0.13% of Cynosure Group's portfolio in Q2 2026, its #51 holding.
  • Cynosure Group first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Cynosure Group's Axsome Therapeutics position peaked at $953K in Q3 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.